Loading
Led MajesTEC-1 and CASSIOPEIA, bringing the first bispecific antibody and daratumumab quadruplets to myeloma.
Philippe Moreau (Nantes) was principal investigator of MajesTEC-1, the pivotal trial of teclistamab, the first BCMA-directed bispecific antibody approved for relapsed myeloma, and of CASSIOPEIA, which established daratumumab with bortezomib-thalidomide-dexamethasone in transplant-eligible patients. He has led IFM trials for two decades including the IFM 2009 transplant study and is a past chair of the IFM.
Shares CD38, CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tags myeloma, bispecific.
Shares CD38, Multiple myeloma and the tags myeloma, trialist.
Shares CD38, Multiple myeloma and the tags myeloma, trialist.
Shares Multiple myeloma and the tags myeloma, trialist.
Shares MajesTEC-1, Teclistamab, BCMA, T-cell engagers (bispecific).
Shares Teclistamab, CD38, BCMA, Bispecific antibodies.
Shares CD38, BCMA, Multiple myeloma and the tag myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, BCMA, CD3.